Outcomes of radiation treatment for prostate cancer. Clinical research interests in the late effects of radiation on normal tissues and chemical modification of radiation injury.
Hodgkins's disease and late effects of radiation and combined modality therapy.
Radiation sensitizers and protectors.
Hypoxic cell cytotoxins.
Esophageal cancers.
General adult and pediatric radiation therapy.

He specializes in genitourinary cancers, such as prostate cancer, bladder cancer, kidney cancer, penile and urethral cancers. He also specializes in radiation and radiosurgery treatment of malignant and benign conditions that affect the central nervous system, including glioblastoma, astrocytoma, oligodendroglioma, meningioma, acoustic neuroma, arteriovenous malformations, and hemangioblastomas associated wtih Von Hippel Lindau syndrome. Dr. Hancock serves on the National Cancer Center Network (NCCN) guidelines panels for Kidney and Testicular cancers. Research activities have involved initial clinical trials of radiation sensitizer and hypoxic cell cytotoxic agents, initial clinical evaluation of the Cyberknife radiosurgical instrument and longitudinal studies of treatment outcomes and late effects of radiation therapy, such as secondary malignancies and radiation associated cardiovascular disease. Current interests are in the application of new imaging and treatment technologies for improving tumor control and minimizing short and long term side effects of radiation and combined modality therapy.